Department of Medicine, DIMED, University of Padova, Italy.
J Med Virol. 2013 Feb;85(2):210-3. doi: 10.1002/jmv.23448. Epub 2012 Nov 14.
This is a case of 62 years old Caucasian treatment-naïve patient who developed a severe acute hepatitis B infection soon after a trip to Thailand. The infection was due to genotype C HBV which was found to be resistant to lamivudine and telbivudine. The patient was treated with tenofovir resulting in complete suppression of viral replication and complete clinical and laboratory remission of acute hepatitis. Later the patient also developed seroconversion of HBeAg to anti-HBe and of HBsAg to anti-HBs. This case demonstrates that mutations of HBV polymerase associated with lamivudine, telbivudine, and adefovir resistance can be present also in untreated patients with severe acute hepatitis B. This suggests that in the clinical context, which represents a life threatening condition, a baseline resistance-testing should be an additional marker in the diagnostic evaluation process. Finally, this case report seems to support the use of tenofovir for the immediate treatment of severe acute hepatitis B.
这是一位 62 岁的高加索裔初治患者,在泰国旅行后不久即发生严重急性乙型肝炎感染。感染是由基因型 C HBV 引起的,该病毒对拉米夫定和替比夫定具有耐药性。患者接受了替诺福韦治疗,导致病毒复制完全抑制和急性肝炎的临床和实验室完全缓解。后来,该患者还发生了 HBeAg 向抗-HBe 和 HBsAg 向抗-HBs 的血清学转换。本病例表明,与拉米夫定、替比夫定和阿德福韦耐药相关的 HBV 聚合酶突变也可能存在于未经治疗的严重急性乙型肝炎患者中。这表明,在危及生命的临床情况下,基线耐药检测应该是诊断评估过程中的一个附加标志物。最后,本病例报告似乎支持使用替诺福韦立即治疗严重急性乙型肝炎。